Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what guidelines are used by NHS services for the diagnosis, referral and treatment of patients with (a) metabolic disorders and (d) generalised or partial lipodystrophy.

Numerous gudielines are used by National Health Service services for the diagnosis, referral and treatment of patients with metabolic disorders. These can be found at the National Institute for Health and Care Excellence (NICE) website:

https://www.nice.org.uk/guidance/conditions-and-diseases/diabetes-and-other-endocrinal--nutritional-and-metabolic-conditions

There are no current NICE guidelines specific to generalised or partial lipodystrophy. NICE is currently developing guidance on the use of metreleptin for the treatment of lipodystrophy through its highly specialised technology evaluation programme. NICE currently expects to issue final guidance in September 2018.

There is also a consensus statement entitled ‘The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline’ published in 2016 by Brown et al. which includes the team from the Severe Insulin Resistance service at Cambridge University Hospitals NHS Foundation Trust:

https://academic.oup.com/jcem/article/101/12/4500/2764979/The-Diagnosis-and-Management-of-Lipodystrophy